HueDx Transforms Point-of-Care Diagnostics with AI-Powered Smartphone Solutions
HueDx’s AI-powered platform improves point-of care diagnostics with enhanced accuracy, real-time data, and wider accessibility for rapid, reliable
testing.
News
Palvella Awarded Up to $2.6 million Grant from the U.S. Food and Drug Administration (FDA) Office of Orphan Products Development to Support Phase 3 Single-Arm, Baseline-Controlled Trial in Microcystic Lymphatic Malformations
FDA Orphan Products Grants are based on scientific and technical merit as determined by rare disease and regulatory experts
Ongoing Phase 3 trial evaluating QTORIN™ 3.9% rapamycin anhydrous gel (QTORIN™ rapamycin) for the treatment of microcystic lymphatic malformations, a program with FDA’s Breakthrough Therapy Designation and Fast Track Designation
Wellsheet and Wolters Kluwer Collaborate to Integrate AI-Powered Clinical Workflows with UpToDate
IVIEW Therapeutics Inc. Completes Patient Recruitment for Phase 1/2 Trial of IVW-1001 Ophthalmic Eyelid Wipe in Dry Eye Disease Patients
The pathogenic role of retinoid nuclear receptor signaling in cancer and metabolic syndromes
Phrase Health Secures NIH SBIR Funding to Advance Innovative Analytics Solutions
Phrase Health, Inc. secures $2M NIH SBIR grant to develop innovative EHR workflow management solutions, advancing patient care through data-driven, continuous improvement.
Delve Health Partners with Strados Labs to Enhance Remote Patient Monitoring in Clinical Trials
Palvella Therapeutics and Pieris Pharmaceuticals Announce Definitive Merger Agreement
Proposed merger to create a Nasdaq-listed, clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for serious, rare genetic skin diseases for which there are no FDA-approved therapies
Combined company is expected to have approximately $80.5 million of cash and cash equivalents at closing, including approximately $78.9 million from an oversubscribed private financing with participation from a syndicate of leading healthcare-dedicated investors, which is expected to provide cash runway into the second half of 2027
Anticipated cash and cash equivalents are expected to fund combined company through multiple clinical trial milestones, including pivotal Phase 3 clinical trial results from a single-arm, baseline-controlled clinical trial of QTORIN™3.9% rapamycin anhydrous gel (QTORIN™ rapamycin) for the treatment of microcystic lymphatic malformations currently being conducted under FDA’s Breakthrough Therapy Designation and Fast Track Designation programs
QTORIN™ rapamycin has the potential to be the first approved therapy and standard of care in the U.S. for microcystic lymphatic malformations and cutaneous venous malformations, if approved
Companies to host joint webcast on Wednesday, July 24 at 8:30am ET